Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | CCKBR | P32239 | 3/20 | 0.53 |
| ▸ | CCKAR | P32238 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.50 |
| ▸ | GRPR | P30550 | 1/20 | 0.49 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 4/20 | 0.49 |
| ▸ | FNTB | P49356 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265201 | 0.90 | PRMT1 (0.53) | PRMT1CCKBRCCKARIL23RGRPR | |
| SCHEMBL30342394 | 0.90 | MAGI3 (0.54) | PRMT1CCKBRCCKARIL23RMAGI3 | |
| SCHEMBL31247979 | 0.87 | CCKBR (0.53) | PRMT1CCKBRIL23RGRPRMAGI3 | |
| SCHEMBL30810352 | 0.87 | PRMT1 (0.57) | PRMT1CCKBRCCKARGRPR | |
| SCHEMBL31018602 | 0.86 | MAGI3 (0.56) | PRMT1CCKBRIL23RGRPRMAGI3 | |
| SCHEMBL30692610 | 0.85 | IL23R (0.59) | CCKBRCCKARIL23RGRPR | |
| SCHEMBL31683350 | 0.84 | CCKBR (0.65) | CCKBRIL23R | |
| SCHEMBL29379665 | 0.83 | CTSC (0.61) | MAGI3ACE | |
| SCHEMBL31442335 | 0.83 | MAGI3 (0.56) | PRMT1CCKBRCCKARIL23RMAGI3 | |
| SCHEMBL29470182 | 0.82 | ACE (0.57) | MAGI3ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066254-A | Human anti-inflammatory peptides for inhalation treatment of inflammatory lung diseases | 阿德维塔生命科学有限责任公司 | 2022-09-16 | — | — | CN | disclosed |